Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
Revised protocol for Irritable Bowel Syndrome (IBS) trial of “GaRP” 200 patient trial successfully implemented and enrolment on track for interim read-out of results anticipated to be no later than in Q2CY2023.
Capital raise by $865,000 Placement and completion of Entitlement Offer to existing shareholders with $524, 691 received.
Board changes with appointment Mr. Nicholas Haslam as non-executive director.